1. Home
  2. BL vs ZYME Comparison

BL vs ZYME Comparison

Compare BL & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BlackLine Inc.

BL

BlackLine Inc.

HOLD

Current Price

$28.88

Market Cap

1.8B

Sector

Technology

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$22.81

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BL
ZYME
Founded
2001
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2016
2022

Fundamental Metrics

Financial Performance
Metric
BL
ZYME
Price
$28.88
$22.81
Analyst Decision
Buy
Strong Buy
Analyst Count
13
11
Target Price
$56.62
$38.90
AVG Volume (30 Days)
980.2K
531.8K
Earning Date
05-05-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
0.13
N/A
Revenue
$177,031,000.00
$105,965,000.00
Revenue This Year
$12.62
$183.10
Revenue Next Year
$10.90
N/A
P/E Ratio
$211.08
N/A
Revenue Growth
43.78
38.87
52 Week Low
$24.70
$11.86
52 Week High
$59.57
$29.75

Technical Indicators

Market Signals
Indicator
BL
ZYME
Relative Strength Index (RSI) 50.08 36.89
Support Level $28.09 $22.20
Resistance Level $31.14 $23.66
Average True Range (ATR) 1.36 0.92
MACD -0.11 -0.30
Stochastic Oscillator 45.77 1.07

Price Performance

Historical Comparison
BL
ZYME

About BL BlackLine Inc.

BlackLine Inc is engaged in providing financial accounting close solutions delivered as Software as a Service (SaaS). The Company's solutions enable its customers to address various aspects of their critical processes, including financial close & consolidation, intercompany accounting, and invoice-to-cash. The majority of the revenue of the company is earned in the United States.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: